BTG2 and breast carcinoma: DCFH-DA, as a marker for ROS detection, was more stained in mast cells isolated in situ from chemotherapy-resistant breast cancer patients, and showed a higher degree of staining in mast cells of the BTG2 low expression group in in vitro cell experiments (Supplementary Figures S3C; Figures 3G, H).